By proceeding, you agree to our Terms of Use and Privacy Policy.
Uniting Key Biopharma and Academics Dedicated to Successfully Developing Exosome-Based TherapeuticsBuilding on the success of the 2022 summit, the 5th Exosome Based Therapeutic Development Summit returns with a refreshed program, with data-driven insights from those pioneering the field who are dedicated to the clinical translation and commercialization of exosome-based therapeutics across a broad range of disease indications.This year features a brand-new focus day on analytical development, diving into characterization assays, purification, and potency assays to enable robust translation into the clinic.This is the most comprehensive, end-to-end meeting for industry personnel who are looking to fine-tune molecular components of exosomes, achieve GMP manufacturing of EVs for clinical applications, and successfully deliver payloads to the target tissue by evaluating route of administration to accelerate candidates towards commercialization.
Unlock the potential of exosome-based therapies and drive medical innovation.
Expand your knowledge through cutting-edge presentations, scientific discussions, and learn about the potential of exosomes in drug delivery and diagnostics.
Engage with a diverse community of researchers, clinicians, and innovators to foster new collaborations and commercial opportunities in exosome-based therapeutics.
Be inspired by breakthrough discoveries, and success stories from pioneers and drive scientific advancements developing life-changing therapies using exosomes.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
At Lonza, we enable #AHealthierWorld by supporting our healthcare customers on the path to commercialization.
Visualizing biomolecular structures through cryo-EM studies can provide insight into multiple stages of the drug development process, from target identification through formulation and manufacturing.
Implementing strategies for single-molecule fluorescence detection in a sheathed flow, NanoFCM provides a versatile and powerful platform —— Flow NanoAnalyzer for the multiparameter analysis of functional nanoparticles (7-500 nm) at the single-partic
RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable Regenerative Medicine industry, one customer at a time.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.